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ABSTRACT 
Introduction. The progression of cancer is a complex process involving host-tumour interactions taking 
place in cancer and in the cancer microenvironment. The tumour remodels the microenvironment into 
the suppressive profile by various mechanisms. One of the most important elements of this mechanism 
is the inducing of the infiltration of Treg lymphocytes into cancer and its microenvironment. The aim of the 
present study was to evaluate the alterations of the Treg cell population in the peripheral blood of patients 
before and after the surgical treatment for endometrial cancer.
Material and methods. For the present study 24 patients with endometrial cancer were recruited. All 
the patients were treated surgically. The peripheral blood samples were collected from the endometrial 
cancer patients before operation and three days after the surgical procedure and evaluated using flow 
cytometry method.
Results. CD25+ CD4+ FOXP3+ T cells were found in all the examined peripheral blood samples derived 
from the endometrial cancer patients in the days before and following applied surgery. We observed 
differences before and after the applied surgical procedure in patients treated for uterine cancer. The 
highest number of Treg cells in the peripheral blood was demonstrated before the surgical procedure; it 
diminished statistically significantly following the surgery.
Conclusions. The decrease of the percentage of Treg cells in blood sera in patients following radical sur-
gical treatment might be useful in measuring the radicalism of the treatment. The monitoring of the level of 
selective immune system suppression related to Treg cell blood serum levels during cancer therapy might 
support a decision to supplement the standard therapy with immunotherapy or to increase the degree of 
radicalism of the applied therapy.
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Introduction
The progression of cancer is a complex process 
involving the host-tumour interactions taking place in 
cancer and in cancer microenvironment. The tumour 
remodels the microenvironment into the suppressive 
profile by various mechanisms. One of the most im-
portant elements of this mechanism is the inducing 
of the infiltration of Treg lymphocytes into cancer and 
its microenvironment. The association between tu-
mour-infiltrating lymphocytes (TIL) and patient survival 
has been demonstrated in many cancer studies [1–3]. 
The classification of CD3+ T cells into functional sub-
sets has led to the subdivision of cytotoxic lymphocytes 
and regulatory lymphocytes. TIL with cytotoxic markers 
are linked with favourable prognosis, while TIL-express-
ing regulatory markers (Tregs) are related with poor 
prognosis [4, 5]. At the beginning Tregs were defined 
by such molecular markers as CD4+ and CD25+ [6]. 
Further studies demonstrated that Tregs express and 
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Table 1. Characteristics of the patients with endometrial 
cancer
Number  
of patients
Age 60.4  
(range 40–82)
Co-morbidities 21 (84%)
Tumour stage according TNM 2010
    T in situ 
    T1a     
    T1b    
    T2
    T3
1 (2.5%)
13 (52%)
6 (24%)
3 (12%)
1 (2.5%)
Lymph node status according 2010
    Without lymph node involvement — N0
    Presence lymph node metastases — N1
22 (88%)
3 (12%)
Distant metastases wg TNM 2010
    M0 absent
    M1 present
25 (100%)
0 (0%)
Tumour differentiation grade
    Grade 1
    Grade 2
    Grade 3
4 (10%)
20 (80%)
1 (2.5%)
Histopathological assessment
    Adenocarcinoma
    Adenosarcoma
    Carcinoma in situ
23 (92%)
1 (4%)
1 (4%)
After operation margin
    > 1cm
    <1cm 
    < 0.5 cm
    Unknown
22 (88%)
1 (4%)
1 (4%)
1 (4%)
Kind of treatment
    Operation
    Brachytherapy
    Radiotherapy
    Chemotherapy
25 (100%)
21 (84%)
2 (8%)
2 (8%)
Response for treatment
    CR complete response
    PR partial response
    SD stabile disease
    PD progression disease
    Death
    Recurrence
23 (92%)
0 (0%)
0 (0%)
0 (0%)
2 (8%)
1 (4%)
functionally depend on the transcription factor fork-
head box protein P3 (FoxP3) [7]. FoxP3 is a well-ac-
cepted marker for Treg cells in cancer studies [7, 8]. 
There are two main subsets of Treg cells: naturally 
occurring, thymic-derived CD4+Treg cells and pe-
ripherally antigen-induced CD4+ T cells derived from 
CD4+CD25 non-Treg cells. Regulatory T cells com-
prise approximately 5–10% of CD4+ T cells [9–13] 
CD4+CD25+ regulatory T cells (Tregs), which express 
the transcription factor FOXP3, suppress cytotoxic im-
mune response, effector T-cell populations including 
CD4+, CD8+ T cells, dendritic cells, macrophages, and 
natural killer cells (NK) [9–13], and can enable tumour 
cells to evade the host immune response. Increased 
numbers of CD4+FOXP3+CD25 high Treg as well as 
high levels of suppressor function have been observed 
in the tissue of various human carcinomas as well as in 
the peripheral circulation of cancer patients. Treg ac-
cumulations in cancer have been generally linked with 
unfavourable disease outcome as reported for many 
human solid tumours [4, 14–17]. It was proposed that 
high Foxp3 expression level may become a marker for 
an immunosuppression level contributing to tumour 
immune escape [14, 15]. In the invasive front of cervical 
cancer Foxp3-expressing T cells were associated with 
invasion and metastasis [19–24]. The malignant neo-
plasm destroys, therefore, the host immune response, 
and the surgical treatment aims to remove the tumour 
mass radically and to restore the immune response. 
It was demonstrated that when the degree of surgery 
radicalism increases the possibility of restoring the 
immune function also increases [25–27]. There is no 
efficient method for the evaluation of surgical treatment 
radicalism. Because Treg cells are the main cell pop-
ulation that enables cancer cells to escape immune 
surveillance, the Treg cell population might correspond 
to a diminishment of the tumour mass in patients and 
might therefore be a marker of the intensity of the selec-
tive suppression of the host immune system and also 
of the degree of radicalism of the surgical procedure.
The aim of the present study was to evaluate the 
alterations of the Treg cell population in the peripheral 
blood of patients before and after surgical treatment for 
endometrial cancer.
Material and methods
Patients
The 24 patients included in the study were treated 
surgically for endometrial cancer between November 
2014 and December 2015 in the Department of Gynae-
cology and Oncology of the Lukaszczyk Oncological 
Centre, Bydgoszcz, Poland. The clinical characteristics 
of patients group are presented in Table 1. 
Patients were treated in line with the accepted 
management standard; in most cases, this included 
combination treatment. The surgical treatment was 
applied primarily in all the patients before the com-
bination treatment, which included radiotherapy, 
brachytherapy, and chemotherapy. Radiotherapy was 
delivered to the pelvis in three patients, 20 patients un-
derwent a brachytherapy, and three required systemic 
treatment. External beam irradiation was delivered at 
doses of 50.4 Gy in 28 fractions. High-dose rate (HDR) 
brachytherapy was performed in 20 patients at doses 
of 10–30 Gy divided into 1–4 fractions. After completion 
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of the treatment, response was observed in 21 patients; 
three of the patients included to our group died because 
of the progression of uterine cancer. Follow-up visits 
were held four weeks after completion of treatment and 
then at three-month intervals. Patient follow-up lasted 
at least 12 months.
The peripheral blood samples were collected from 
the endometrial cancer patients before operation and 
three days after the surgical procedure. The patient’s 
consent was obtained in each case. 
Flow cytometry
The samples for the cytometric analysis of the Treg 
cell population in the whole blood of patients were 
prepared using Human Regulatory T Cell Staining 
Kits (eBioscience), according to the manufacturer’s 
instruction with some minor modifications. To the 100 µL 
of blood, 15 µL of CD4 FITC and CD25 PE cocktail, as 
well as 5 µL of CD45 APC-Cy7 (Becton Dickinson; BD 
Biosciences Pharmingen, San Jose, CA, USA), were 
added. After 30 min of incubation with mAbs (in the 
dark at 4°C), the cells were washed with Flow Cytometry 
Staining Buffer, centrifuged for 5 min at 350 × g, and 
then permeabilised with freshly prepared fixation/per-
meabilisation buffer (for 40 min in the dark at 4°C). 
Next, the cells were washed twice by adding 1 × per-
meabilisation buffer, blocked by normal rat serum (for 
15 min in the dark at 40°C) and subsequently stained 
with anti-human FoxP3 APC antibody or rat IgG2a k APC 
antibody (in the case of isotype control) for 35 min in 
the dark at 40°C. After another washing step, the cells 
were suspended in Flow Cytometry Staining Buffer and 
analysed using a BD FACS Canto II flow cytometer and 
BD FACS Diva Software (Becton Dickinson). In each 
sample, 3 × 104 lymphocytes were collected and gated 
on SSC × CD45 APC-Cy7 dot-plot. Next, the popula-
tions of CD4+ FITC, CD25+ PE, and double positive 
CD4 and CD25 cells were distinguished among the 
lymphocytes. Finally, the gate of FoxP3 positive cells 
was established on the CD4+/CD25+ subpopulation. 
For each sample, a negative control was performed 
to measure autofluorescence, and an isotype control 
was performed to exclude non-specific staining of 
specific antibodies.
Statistical analysis
The distribution of variables in the study groups of 
women checked with the use of the Shapiro–Wilk test 
showed that each of the women was different from nor-
mal. The statistical significance between the groups was 
determined by the Kruskal-Wallis test, one-way analysis 
of variance by ranks. The Mann-Whitney U test was then 
used as applicable. All statistical analyses were carried 
out with the Statistica 8.0 software program (StatSoft Inc., 
Tulsa, OK, USA). A p value < 0.05 was considered 
indicative of statistical significance.
Results
CD25+ CD4+ FOXP3+ T cells were found in all the 
examined peripheral blood samples derived from the 
endometrial cancer patients in the days before and fol-
lowing applied surgery. We observed differences before 
and after the surgical procedure in patients treated for 
endometrial cancer. The highest number of Treg cells 
in the peripheral blood was demonstrated before the 
surgical treatment; it diminished statistically significantly 
following the surgery.
1. The percentage of Foxp3-positive cells within CD4+ 
lymphocytes was statistically significantly higher in 
patients with endometrial cancer before the surgery 
than after the surgery (p < 0.05). 
2. No statistically significant differences in the percent-
age of CD4+CD25+ positive lymphocytes within the 
population of CD4+ lymphocytes were observed in 
relation with the surgery — Figure 1.
3. A statistically significant decrease in the percentage 
of CD4+CD25+ positive lymphocytes within the 
population of T lymphocytes was observed following 
the surgery (p < 0.05). 
4. A statistically significant decrease in the percentage 
of Foxp3+ lymphocytes within the population of 
CD4+CD25+ following the surgical treatment was 
observed (p<0.003) — Figure 2.
5. A statistically significant decrease in the percent-
age of Foxp3+ lymphocytes within the population 
of CD4+ (p < 0.05) was observed following the 
surgical treatment.
No statistically significant differences were identified 
between the analysed antigens and the age, haemo-
globin level, white blood cells, platelet count, the type 
of the treatment applied before the surgery such as 
radiotherapy, brachytherapy, concomitant diseases, 
T-staging, FIGO classification, tumour differentiation 
grade G, lymph node status, and presence of lesions 
in the cervix.
Discussion
In the present study it was demonstrated that 
surgical treatment in endometrial cancer influences 
significantly the percentages of T lymphocyte subpop-
ulations in blood sera. Statistically significant decreases 
of the percentage of Foxp3+CD4+CD25+ lymphocytes 
within the population of CD4+CD25+ lymphocytes and 
within the population of CD4+ T lymphocytes were 
observed following the surgical treatment. A similar 
observation was noted in ovarian cancer, where the 
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Figure 2. The percentage of Foxp3+ lymphocytes within 
the population of CD4+CD25+ positive lymphocytes 
in relation with the surgery. The statistically significant 
decrease in the percentage of Foxp3 positive lymphocytes 
was observed following the surgical treatment
Figure 1. The percentage of CD4+CD25+ positive 
lymphocytes within the population of CD4+ 
lymphocytes in relation with the surgery. No 
statistically significant differences were observed in 
the percentage of CD4+CD25+ positive lymphocytes 
within the population of CD4+ positive lymphocytes 
with respect to the surgery
percentages of FOXP3+ cells in the subpopulation of 
CD4+ T lymphocytes found in the peripheral blood of 
the patients before the surgical procedure were statis-
tically significantly higher than those observed in the 
peripheral blood of the same patients after the surgical 
procedure [27]. The suppressive microenvironment in 
endometrial cancer is thus created by the recruitment of 
Treg cells into the tumour and its stroma and leads to an 
increase of the percentage of Treg cell population in the 
blood serum observed in various cancer patients [7, 8]. 
In murine models, depletion of Treg cells was observed 
to promote tumour rejection or inhibit the tumour growth 
[28, 29]. In uterine cancer, the frequency of Treg cells 
in peripheral blood mononuclear cells in blood serum 
was prominently increased, independently of the stage 
of disease [28, 29]. 
The decrease of the percentage of Treg cells in 
blood sera in patients following radical surgical treat-
ment might be useful in measuring the radicalism of 
the treatment. The monitoring of the level of selective 
immune system suppression related to Treg cell blood 
serum levels during cancer therapy might support 
a decision to supplement the standard therapy with 
immunotherapy or to increase the degree of radicalism 
of the applied therapy. 
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